

Special Issue

Advances in Small Bowel Disorders: From Basic Research to Technical Developments

Message from the Guest Editors

The small bowel is essential for the breakdown and absorption of nutrients, gut microbiome regulation, and immune system modulation, playing a key role in health and disease. Notwithstanding, this organ is often overlooked as it poses significant challenges for clinicians in terms of accurate diagnosis and effective treatment. The developments in diagnostic technologies, such as capsule endoscopy and device-assisted enteroscopy, have greatly improved our ability to diagnose and manage small bowel diseases. Additionally, a multidisciplinary approach with straight collaboration between gastroenterologists, pathologists, radiologists, and surgeons is key to successfully managing small bowel disorders. The forthcoming Special Issue focuses on several elements that are essential for understanding small bowel disorders. The invited topics include, but are not limited to, the following:

- Small bowel capsule endoscopy;
- Device-assisted enteroscopy;
- Artificial intelligence;
- Computer-aided diagnosis;
- Suspected small bowel bleeding;
- Physiopathology of small bowel diseases (immunology, inflammation, gut microbiome, infections, and ischemia);
- Small bowel malignancies.

Guest Editors

Dr. Maria Manuela Estevinho

1. Department of Gastroenterology, Vila Nova de Gaia Espinho Hospital Center, Vila Nova de Gaia, Portugal
2. Unit of Pharmacology and Therapeutics, Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal

Dr. Rolando Pinho

Department of Gastroenterology, Vila Nova de Gaia/Espinho Hospital Center, Vila Nova de Gaia, Portugal

Deadline for manuscript submissions

closed (31 March 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/170555

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).